Viking Therapeutics’ $93.39 Target Implies 175% Upside, but 2027 Data Delay Limits 2026 Rally
Wall Street's average $93.39 price target for Viking Therapeutics implies 175% upside, but its pivotal VK2735 phase 3 data won't arrive until 2027, making a 2026 surge unlikely. VK2735’s phase 1 maintenance study of oral and injectable regimens may differentiate the drug but is unlikely to boost shares materially this year.
1. Wall Street Price Target Suggests 175% Upside
Viking Therapeutics (VKTX) carries an average Wall Street price objective of $93.39, implying a 175% gain from current trading levels. This consensus is based on inputs from 15 analysts tracked by Yahoo Finance, reflecting optimism about Viking’s lead candidate VK2735 and its long-term commercial potential in the rapidly expanding GLP-1 weight-management space. While the implied upside is substantial, reaching that level in 2026 would require a major positive catalyst well in excess of what the company can realistically deliver this year.
2. Phase III Readout Not Expected Until 2027
The pivotal 78-week phase III study of subcutaneous VK2735 completed enrollment in late 2025, making a full data release unlikely until 2027. Viking has not confirmed plans for an interim analysis for efficacy or safety in 2026, leaving investors without a near-term inflection point. Given that late-stage trial results typically drive the most significant share price moves in biotechnology, the absence of such data this year undermines the feasibility of a 175% rally in 2026.
3. Maintenance Study Could Differentiate VK2735
Separately, Viking is conducting a phase I maintenance study evaluating daily oral, weekly oral and monthly injectable formulations of VK2735 in patients who have already achieved weight loss. If this small trial demonstrates that alternate dosing regimens sustain or enhance weight-loss durability, it would position VK2735 competitively against existing therapies. However, primary endpoints in phase I focus on safety and tolerability, meaning strong efficacy signals—and corresponding stock-moving impact—are unlikely in the near term.
4. Long-Term Upside Hinges on Pipeline and Execution
Investors with multi-year horizons may find Viking attractive despite 2026’s sparse catalyst calendar. VK2735 has delivered robust mid-stage results, and the company plans late-stage studies in diabetic populations—an underserved segment with high growth potential. Meanwhile, VK2809, Viking’s candidate for metabolic dysfunction-associated steatohepatitis, has shown favorable mid-stage data, and a next-generation weight-loss program is slated to enter clinical trials. Achieving positive clinical milestones across these programs over the next five years would justify Wall Street’s bullish projections, but execution risk remains elevated.